Pancreatic Cancer Research

ResearcherTongji UniversityNo recent work listed

Min Shi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2130-181X; OpenAlex author ID A5100695144. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 4 papers · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper

Papers 8

  1. Identification of KRAS G12V associated clonal neoantigens and immune microenvironment in long-term survival of pancreatic adenocarcinoma. First author DOI 10.1007/s00262-021-03012-4↗
  2. CD13hi Neutrophil-like myeloid-derived suppressor cells exert immune suppression through Arginase 1 expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/2162402x.2016.1258504↗
  3. FOXM1 promotes the warburg effect and pancreatic cancer progression via transactivation of LDHA expression. First author DOI 10.1158/1078-0432.ccr-13-2407↗
  4. A novel KLF4/LDHA signaling pathway regulates aerobic glycolysis in and progression of pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-14-0186↗
  5. Targeting miRNAs for pancreatic cancer therapy. Co-author DOI 10.2174/1381612820666140128210443↗
  6. Upregulation of miR-194 contributes to tumor growth and progression in pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/or.2013.2960↗
  7. Diagnostic and biological significance of microRNA-192 in pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/or.2013.2420↗
  8. Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance. Co-author DOI 10.3748/wjg.v18.i8.840↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jun Zhang Zhang · 2 shared papers, 2014–2022 · strength 0.18
  2. Keping Xie · 3 shared papers, 2014 · strength 0.15
  3. Chenyan Zhao · 3 shared papers, 2013–2017 · strength 0.14
  4. Chao Wang · 1 shared paper, 2022 · strength 0.14
  5. Henghui Zhang · 1 shared paper, 2022 · strength 0.14
  6. Yong Gao · 2 shared papers, 2014 · strength 0.09
  7. Daoyan Wei · 2 shared papers, 2014 · strength 0.09
  8. Jiujie Cui · 2 shared papers, 2014 · strength 0.09
  9. Ming-hua Zhu · 2 shared papers, 2013–2014 · strength 0.08
  10. Jing Zhang · 2 shared papers, 2013–2014 · strength 0.08
  11. Qinghua Liu · 2 shared papers, 2013–2014 · strength 0.08
  12. Shu‐Hui Zhang · 2 shared papers, 2013–2014 · strength 0.08
  13. Xiongfei Xu · 1 shared paper, 2017 · strength 0.06
  14. Gang Y Jin · 1 shared paper, 2017 · strength 0.06
  15. Biao Yang · 1 shared paper, 2017 · strength 0.06
  16. Jing Zhang · 1 shared paper, 2017 · strength 0.06
  17. Ying Chen · 1 shared paper, 2017 · strength 0.06
  18. Shiwei Guo · 1 shared paper, 2017 · strength 0.06
  19. Minghua Zhu · 1 shared paper, 2017 · strength 0.06
  20. Guiling Ding · 1 shared paper, 2017 · strength 0.06
  21. Yan Gu · 1 shared paper, 2017 · strength 0.06
  22. Dacheng Xie · 1 shared paper, 2014 · strength 0.04
  23. Jiawei Du · 1 shared paper, 2014 · strength 0.04
  24. Shaojiang Zheng · 1 shared paper, 2014 · strength 0.04
  25. Ying Chen · 1 shared paper, 2013 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.